尊龙凯时·(中国)人生就是搏!

Founded in 1985, Tonghua Dongbao Pharmaceutical Co., Ltd. has built a solid reputation as a pharmaceutical manufacturer that boasts strengths in the R&D, production, and marketing of pharmaceuticals, particularly Chinese patent medicines, chemical medicines, and biological products. Our most lauded products include Zhennaoning Capsules, Dongbao Gantai Tablets, Tangjierui Repaglinide Tablets, Tangjieen Engagliflozin Tablets, Gansulin® Recombinant Human Insulin, and Pingsulin® Insulin Glargine, and Ruisulin® Insulin Aspart, and Tongboli Liraglutide. Tonghua Dongbao was listed on the Shanghai Stock Exchange in August 1994.

Over the years, we have maintained our philosophy of establishing a global brand through consistent innovation. Tonghua Dongbao developed the first Chinese made human insulin, with the trade name Gansulin, in 1998. Gansulin thus established China as the world’s third producer of recombinant human insulin following the United States and Denmark, and helped China overcome years of dependence on imports of the medicine. This achievement won the second prize of the National Science and Technology Progress Award and was listed in the "Top 10 Scientific Breakthroughs 1998". Tonghua Dongbao was also awarded many honorary titles such as National Technology Innovation Demonstration Enterprise and National High-tech Enterprise, and Dongbao® and Gansulin® were recognized as China’s well-known trademarks.

In June 2008, Tonghua Dongbao successfully commercialized the research results to expand the annual production capacity of recombinant human insulin drug substances to 3,000 kg and became the first EU cGMP-certified biopharmaceutical manufacturer in China. Tonghua Dongbao began to build the third manufacturing plant of recombinant human insulin and the production lines of insulin glargine and insulin aspart in 2012 and 2014 respectively. We have an annual production capacity of over 300 million cartridges & vials now. In 2016, we started to invest in the construction of the Biopharmaceutical Industrial Park, which includes: Pharmaceutical Research Institute of Tonghua Dongbao and Quality Testing Center, production bases of insulin degludec, liraglutide drug substances and injection, wastewater treatment plant, acetonitrile recycling station, etc. Tonghua Dongbao Pharmaceutical Research Institute has begun operations since March 2021.

Our insulin analog: insulin glargine, insulin aspart, insulin aspart mix 70/30 and mix 50/50 have been available on the market since February 2020, December 2021, and December 2022 respectively. GLP-1RA Liraglutide injection approved for marketing in December 2023. In addition, we have 4 oral anti-diabetic hypoglycemic drugs obtained the Pharmaceutical Product Registration Certificate issued by NMPA: sitagliptin phosphate tablets, sitagliptin phosphate/metformin hydrochloride tablets, repaglinide tablets, engagliflozin tablets. Besides, etoricoxib tablets received the notice of acceptance from the NMPA on the NDA application in September 2023.

Today, Tonghua Dongbao provides the world with five novel drugs, including three for diabetes and two for gout. Among them, first subject enrolled in Phase I clinical trial on first Chinese-made dual-target inhibitor for gout (THDBH151 Tablets) in May 2023, novel URAT1 inhibitor for gout meets primary endpoint in phase II clinical trial in January 2024. In diabetes therapy area, first subject enrolled in Phase I clinical trial on GLP-1/GIP receptor agonist (THDBH120 Injections) and oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules) in December 2023.

Tonghua Dongbao advances its international strategy continuously. Based upon domestic market, while further expanding overseas markets. Tonghua Dongbao has an international registration team and an overseas sales team for international business expansion. We have already established business contacts with key regional clients in Southeast Asia, the Middle East, East Asia, South America, and Africa, and have established strategic cooperation with multiple well-known domestic enterprises, to explore overseas market jointly. Besides, in early 2020, we started filing for the registration of insulin glargine and insulin lispro in the European Union and other developing countries.

In the days to come, we will stay true to our philosophy of establishing a global brand through consistent innovation. We will enhance our capabilities in innovation-driven biopharmaceutical R&D and scale up the commercialization of research results to contribute toward achieving the goal of health for all.